Cincinnati Eye Institute, Southwest Ohio
2 clinical trials · Sponsor
◉ Watch Cincinnati Eye Institute, Southwest Ohio
| Record | Firm | Date |
|---|---|---|
| A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome (NCT07695298) | Cincinnati Eye Institute, Southwest Ohio | 2026-07-01 |
| Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial (NCT06541574) | Cincinnati Eye Institute, Southwest Ohio | 2024-03-01 |
Track Cincinnati Eye Institute, Southwest Ohio automatically
Every clearance here is in the API, with alerts when new ones post.